Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder" }, "data": [ { "type": "Grant", "id": "15679", "attributes": { "award_id": "1R01HL176493-01", "title": "Pathogenic Mechanism and Therapeutic Approaches for Exercise Intolerance in Post-Acute Sequelae of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32514, "first_name": "EMMANUEL FRANCK", "last_name": "MONGODIN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-04-01", "end_date": "2029-01-31", "award_amount": 633045, "principal_investigator": { "id": 32524, "first_name": "Michael G", "last_name": "Risbano", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32525, "first_name": "Lianghui", "last_name": "Zhang", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Post-acute sequelae of COVID-19 (PASC) is an emerging public health priority with up to 18% prevalence. Noteably, almost 30% patients diagnosed with PASC experence exercise intolerance. This activity limitation continues to negatively impact our workforce, and poses a persistent socialeconimic burden on our society. Our Post-Covid Recovery Clinic, a RECOVERY Vital site, has evaluated exercise intolerant PASC for nearly 4 years. We recently discovered pathophysiologic endotypes that contribute to exercise intolerance in PASC via invasive cardiopulmonary exercise testing (iCPET). Yet, the molecular drivers for this population remain elusive. Four- years after the onset of the pandemic we are left without PASC-defining biomarkers, or targeted therapeutics. Thus, it is crucial to investigate the interconnected molecular and pathophysiologic links in exercise intolerant PASC, a task uniquely within our team’s expertise. Angiotensin-converting enzyme 2 (ACE2) is not just an entry receptor for SARS-CoV-2 but also an enzyme with a protective function through regulation of the renin- angiotensin system. Studies have shown that a high level of plasma ACE2 is associated with an increased risk of SARS-CoV-2-related mortality. Our preliminary data showed that the catalytic activity of increased plasma ACE2 was significantly impaired in the exercise intolerant PASC patients, and closely correlated with reduced exercise capacity as measured by peak oxygen consumption evaluated during iCPET. Furthermore, to study the pathogenic mechanism of exercise intolerance in PASC, we established a novel PASC mouse model. In this model, we observed the persistence of the SARS-CoV-2 RNAs in lung microvascular ECs, impaired ACE2 activity, chronic pulmonary inflammation, along with a significant reduction in exercise capacity. Thus, we hypothesize that dysfunctional ACE2 shed from pulmonary ECs is a major driver for exercise intolerance in PASC and an engineered solube ACE2 with enhanced ACE2 activity will improve exercise capacity of PASC. To test our hypotheses, we will investigate the predictive value of ACE2 activity as a clinical biomarker and assess its association with exercise capacity over 12 months in PASC patients in Aim 1. We will define an engineered soluble ACE2 with enhanced ACE2 activity as an innovative therapeutic intervention to improve exercise capacity and vascular function in the PASC mouse model in Aim 2. Furthermore, we will explore the mechanism of ACE2 dysfunction shed from the pulmonary vasculature in Aim 3. If successful, we will identify a diagnostic and therapeutic paradigm urgently needed for PASC patients experiencing exercise intolerance, and remediate the deficient response to this global public health threat.", "keywords": [ "2019-nCoV", "ACE2", "Acute Lung Injury", "Adult", "Affect", "Binding", "Biological Markers", "Blood Vessels", "COVID-19", "COVID-19 mortality", "COVID-19 patient", "Cardiopulmonary", "Cell surface", "Characteristics", "Chronic", "Circulation", "Clinic", "Clinical assessments", "Data", "Diagnosis", "Diagnostic", "Disease Progression", "Disintegrins", "Endothelial Cells", "Endothelium", "Engineering", "Enzymes", "Exercise", "Exercise Test", "Fatigue", "Functional disorder", "Health", "Impairment", "Inflammation", "Knock-in", "Knockout Mice", "Left", "Link", "Long COVID", "Lung", "Measures", "Medicine", "Metalloproteases", "Modeling", "Molecular", "Outpatients", "Oxygen Consumption", "Pathogenicity", "Pathology", "Patients", "Peptides", "Plasma", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predictive Value", "Prevalence", "Proteins", "Public Health", "Pulmonary Inflammation", "Questionnaires", "RNA", "Recovery", "Regulation", "Renin-Angiotensin System", "Risk", "SARS-CoV-2 infection", "Site", "Societies", "Symptoms", "Testing", "Therapeutic", "Therapeutic Intervention", "clinical biomarkers", "clinical infrastructure", "design", "dosage", "endothelial dysfunction", "exercise capacity", "exercise intolerance", "experience", "improved", "innovation", "knock-down", "lung microvascular endothelial cells", "mortality", "mouse model", "novel", "pandemic disease", "post SARS-CoV-2 infection", "post-COVID-19", "public health priorities", "receptor", "remediation", "research clinical testing", "response", "symptom cluster", "targeted treatment", "treatment optimization" ], "approved": true } }, { "type": "Grant", "id": "10315", "attributes": { "award_id": "1R21HL165405-01", "title": "Changes in the public health burden of tobacco use during the COVID-19 pandemic: the C4R Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 26216, "first_name": "Lisa", "last_name": "Postow", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-07-31", "award_amount": 246750, "principal_investigator": { "id": 26275, "first_name": "Pallavi P", "last_name": "Balte", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 24266, "first_name": "Elizabeth", "last_name": "Oelsner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary/Abstract Tobacco product use has been well established as a major cause of death and disease, yet the public health burden of tobacco in the context of the COVID-19 pandemic – which has already killed more than 700,000 Americans and radically altered behaviors and health in populations across the world – remains incompletely understood. Emerging evidence suggests that the personal and societal disruption of the COVID-19 pandemic has led to changes in tobacco use patterns. Reports from early in the COVID-19 pandemic provided inconsistent estimates of associations between tobacco use and risk of severe COVID-19, with some studies suggesting that smokers were at lower relative risk. This application will characterize the impact of the COVID-19 pandemic on tobacco use patterns and the association between pre-COVID tobacco use and the risk and severity of COVID- 19 illness. We will test these hypotheses in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R), a nationwide study of 14 population-based multi-ethnic NIH funded cohorts, which is assessing self-reported cigarette and e-cigarette use using standardized questionnaires in over 45,000 cohort participants in whom extensive prior harmonization of pre-pandemic tobacco use patterns, socio-demographics, psychosocial factors, and comorbidities over >1 million person-years of follow-up are available. C4R is also ascertaining COVID-19 cases via questionnaires, with active surveillance in a subset, and validating cases via SARS-CoV-2 serology and protocolized events adjudication. C4R has already collected over 45,000 COVID questionnaires, over 10,000 dried blood spots for SARS-CoV-2 serology, and over 1,000 COVID-related events that are undergoing adjudication. In Aim 1, we will identify and examine changes in cigarette and e-cigarette status, intensity of use, and product mix use during the pandemic period (2020-22) compared to pre-pandemic tobacco use trajectories (1971-2019). These changes will be assessed in association with socio-demographics, psychosocial factors, comorbidities, COVID risk mitigation behavior (including vaccination), and history of COVID-19 illness. In Aim 2, we will assess whether COVID-19 outcomes, including post-acute sequelae of SARS-CoV-2 infection (PASC), are associated with pre-COVID non-cigarette tobacco use patterns (pipe, cigar, and e-cigarette), with comparison to cigarette use and never tobacco-use. Accomplishment of the Aims will support targeted public health interventions to promote smoking avoidance and cessation among groups at high risk of tobacco initiation or relapse. It will also provide valid information on whether tobacco use increases the relative risk of adverse pandemic-era health outcomes, severe COVID-19 or PASC, which will be suitable to inform public health policy and regulation.", "keywords": [ "2019-nCoV", "Adult", "American", "Behavior", "Behavioral", "Biochemical", "Blood", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "COVID-19 risk", "COVID-19 severity", "Cause of Death", "Cigar", "Cigarette", "Clinical", "Cohort Studies", "Data", "Disease", "Electronic Health Record", "Electronic cigarette", "Epidemiology", "Event", "Funding", "General Population", "Health", "Health Campaign", "Health Policy", "Individual", "Long COVID", "Measurement", "Measures", "National Heart Lung and Blood Institute", "Outcome", "Outcomes Research", "Participant", "Patient Self-Report", "Pattern", "Persons", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Proportional Hazards Models", "Protocols documentation", "Psychosocial Factor", "Public Health", "Questionnaires", "Recording of previous events", "Regulation", "Relapse", "Relative Risks", "Reporting", "Research", "Research Personnel", "Resources", "Risk", "SARS-CoV-2 infection", "Sampling", "Serology", "Severities", "Smoker", "Smoking", "Social Desirability", "Spottings", "Standardization", "Testing", "Time", "Tobacco", "Tobacco use", "United States National Institutes of Health", "Vaccination", "Work", "adjudication", "base", "cigarette smoking", "cohort", "comorbidity", "coronavirus disease", "electronic cigarette use", "follow-up", "high risk", "mortality", "multi-ethnic", "non-cigarette tobacco product", "pandemic disease", "population based", "psychologic", "public health intervention", "research study", "risk mitigation", "risk stratification", "severe COVID-19", "social", "sociodemographics" ], "approved": true } }, { "type": "Grant", "id": "10299", "attributes": { "award_id": "1R01AG078181-01", "title": "Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8478, "first_name": "John", "last_name": "Williams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-15", "end_date": "2027-04-30", "award_amount": 476442, "principal_investigator": { "id": 26253, "first_name": "Ahmet", "last_name": "Hoke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26254, "first_name": "Kannan", "last_name": "Rangaramanujam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26255, "first_name": "Barbara Stauch", "last_name": "Slusher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Age-related loss of muscle mass, or sarcopenia, is a hallmark of aging that affects up to 20% of those over 65 and up to 50% of those over 80, for which there are no pharmacological treatments. We recently discovered that the enzyme Glutamate Carboxypeptidase II (GCPII), which catalyzes the hydrolysis of N-acetylaspartylglutamate (NAAG) to glutamate, is highly upregulated in activated macrophages infiltrating muscle during aging, and that inhibiting the elevated GCPII activity with the inhibitor 2-PMPA (IC50 = 0.3nM) dramatically delays neuromuscular junction (NMJ) denervation, and muscle function and volume loss. Unfortunately, 2-PMPA is not clinically developable. It is highly polar, with negligible oral bioavailability (F<2%), a short half-life (<30m), and is active only with high systemic (IP) doses. Given its significant clinical potential, we propose to address these limitations by utilizing hydroxyl-dendrimers to facilitate its sustained and targeted delivery. Hydroxyl-dendrimers have shown promise as targeted delivery systems due to their size (~4-10 nm) and surface attributes. They are rapidly cleared from circulation under normal conditions but are selectively engulfed and retained by activated and phagocytic immune cells under injury or inflammatory conditions. This is a very translational approach, as targeted dendrimer delivery has been demonstrated to be efficacious in multiple animal models and recently shown to reduce inflammation and mortality in a Ph2 clinical trial in hospitalized patients with severe Covid-19 (NCT04458298). We have assembled a highly experienced team with extensive expertise in neuromuscular disorders and aging (Hoke), dendrimer nanoparticles (Kannan), and animal pharmacology, pharmacokinetics, and clinical translation (Slusher). Together we plan to develop dendrimer-2PMPA (D-2PMPA) for age-related sarcopenia by implementing the following aims: AIM 1. Synthesize and characterize generation 4 (G4) and generation 6 (G6) D-2PMPA conjugates. AIM 2. Assess D-2PMPA (G4 and G6) pharmacokinetics, target engagement, and biodistribution in aged mice. AIM 3. Evaluate the efficacy (behavioral, electrophysiological, and histological) and tolerability of the selected D-2PMPA conjugate in aged mice. Successful execution of these aims will result in a D-2PMPA conjugate ready for IND-enabling studies to support future clinical studies to combat age-related sarcopenia.", "keywords": [ "Acids", "Address", "Adult", "Affect", "Aging", "Animal Model", "Animals", "Autopsy", "Behavioral", "Biodistribution", "Biological Availability", "Blood Circulation", "Body Weight", "Caliber", "Cells", "Charge", "Chronic", "Clinical", "Clinical Chemistry", "Clinical Research", "Clinical Trials", "Dendrimers", "Denervation", "Development", "Disease", "Dose", "Drug Kinetics", "Economic Burden", "Electromyography", "Electrophysiology (science)", "Enzymes", "FOLH1 gene", "Fiber", "Fracture", "Future", "Generations", "Glutamates", "Half-Life", "Hand Strength", "Health Care Costs", "Histologic", "Hospitalization", "Human", "Hydrolysis", "Hydroxyl Radical", "Immune", "Infiltration", "Inflammation", "Inflammatory", "Injury", "Kinetics", "Label", "Lead", "Link", "Liquid substance", "Locomotion", "Magnetic Resonance Imaging", "Maintenance", "Measures", "Microglia", "Mus", "Muscle", "Muscle function", "N-acetylaspartylglutamate", "Neuromuscular Diseases", "Neuromuscular Junction", "Neuropeptides", "Neurotransmitters", "Oral", "Pathologic", "Patients", "Penetration", "Phagocytes", "Pharmaceutical Preparations", "Pharmacological Treatment", "Pharmacology", "Physical Function", "Physiological", "Plasma", "Play", "Population", "Prevention", "Risk", "Role", "Source", "Stains", "Stomach", "Surface", "System", "Testing", "Tissues", "Weight", "age related", "age-related muscle loss", "aged", "clinical translation", "combat", "cyanine dye 5", "effective therapy", "efficacy evaluation", "experience", "falls", "fracture risk", "glutamatergic signaling", "in vivo", "inhibitor", "macrophage", "mortality", "muscle aging", "muscle form", "nanoparticle", "nerve supply", "pinacolyl methylphosphonic acid", "sarcopenia", "severe COVID-19", "small molecule", "targeted delivery", "translational approach", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "5492", "attributes": { "award_id": "3U24AI152172-02S1", "title": "A scalable platform for highly-multiplexed analysis of antibody reactivity from <1uL of blood", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19123, "first_name": "John A.", "last_name": "Peyman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-29", "end_date": "2023-03-31", "award_amount": 337934, "principal_investigator": { "id": 19124, "first_name": "John", "last_name": "Altin", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 743, "ror": "", "name": "TRANSLATIONAL GENOMICS RESEARCH INST", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Antibodies are highly-specific, diverse and widely-assayed biomarkers used to determine recent or historical pathogen exposures, measure the protection conferred by a vaccine, understand the basis of autoimmune diseases or evaluate a host's immunological function. Traditional assays for antibodies focus on one or a small number of reactivities at a time, and so are incommensurate with the scale and diversity of an individual's antibody response. A tool to more holistically interrogate this diversity of reactivities using a small sample volume would enable a new generation of studies in systems immunology, disease association, and epidemiological surveillance. Here, we propose to optimize and significantly extend an approach we have developed for highly- multiplexed, reproducible and inexpensive assays that enable sensitive and high-resolution analysis of antibody reactivity across 100,000s of antigens from <1µL of blood. Our approach takes advantage of a rapid, fully-in- vitro method for generating 100,000s of DNA-barcoded peptides (`PepSeq') as probes for the highly-multiplexed interrogation of serum antibodies using DNA sequencing. As a proof-of-concept, we will be focusing here on an assay targeting all viruses known to infect humans (i.e., the human virome). The virome is an ideal use case for this technology, as viruses represent an incredibly diverse and ubiquitous challenge to the immune system, and because of their small genome sizes, the complete virome can be covered within a single library with minimal loss of diversity. Our preliminary data with this virome assay establishes the feasibility of this approach. Here, we will optimize the assay procedures for multiple sample types in order to increase sensitivity and specificity, while decreasing cost. We will also establish standardized protocols for isotype-specific profiling, adapt the technology to enable antigen-specific, single-cell characterization, and build a suite of open access data analysis and visualization tools to facilitate the use of this technology by the broader research community. Throughout this process, we will generate a panel of anti-virome antibody profiles, including a cohort profiled longitudinally – this data will be made available to the community through the ImmPort portal. If successful, this project will deliver: (i) an optimized assay SOP and library for comprehensive evaluation of pan-viral immunity using a small sample volume, (ii) a large set of publicly-available anti-virome immunity datasets, and (iii) a framework for multiplexed serological assay development that can be directly extended to other targets.", "keywords": [ "Allergens", "Amino Acids", "Antibodies", "Antibody Response", "Antigens", "Antiviral Agents", "Autoantigens", "Autoimmune Diseases", "B-Lymphocytes", "Bar Codes", "Basic Science", "Benchmarking", "Biological Assay", "Biological Markers", "Blood", "Blood specimen", "Cells", "Clinical Research", "Communities", "Custom", "DNA", "DNA sequencing", "Data", "Data Analyses", "Data Set", "Databases", "Disease", "Drops", "Epidemiologic Monitoring", "Evaluation", "Event", "Exposure to", "Frequencies", "Generations", "Genome", "Gold", "Human", "IgE", "Immune response", "Immune system", "Immunity", "Immunoglobulin A", "Immunoglobulin G", "Immunoglobulin M", "Immunologic Monitoring", "Immunology", "In Vitro", "Individual", "Length", "Libraries", "Link", "Measures", "Methods", "Monitor", "Mutagenesis", "Peptides", "Performance", "Plasma", "Population", "Procedures", "Process", "Production", "Proteins", "Protocols documentation", "Reproducibility", "Research", "Resolution", "Resources", "Sampling", "Sensitivity and Specificity", "Serology test", "Seroprevalences", "Serum", "Signal Transduction", "Specificity", "Spottings", "Standardization", "System", "Technology", "Testing", "Time", "Vaccines", "Variant", "Viral", "Viral Antibodies", "Virus", "Visualization software", "assay development", "cohort", "cost", "data access", "data visualization", "design", "human virome", "immune function", "longitudinal analysis", "open data", "pathogen", "pathogen exposure", "single cell sequencing", "success", "tool", "transcriptome", "transcriptome sequencing", "transcriptomics", "virome" ], "approved": true } }, { "type": "Grant", "id": "5518", "attributes": { "award_id": "3P20GM103395-20S3", "title": "Surveillance of SARS-CoV-2 in Alaska", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19190, "first_name": "Sheila", "last_name": "Caldwell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-24", "end_date": "2024-07-31", "award_amount": 128440, "principal_investigator": { "id": 19191, "first_name": "BRIAN M", "last_name": "BARNES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 751, "ror": "https://ror.org/01j7nq853", "name": "University of Alaska Fairbanks", "address": "", "city": "", "state": "AK", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: To date (3/23/21), Alaska has suffered over 58,000 cases of COVID-19, 1,318 hospitalizations, and 306 deaths. Alaska is a designated Primary Care Health Professional Shortage Area. Likely driven by health disparities, the COVID-19 fatality rate among American Indian/Alaska Native (AI/AN) residents of Alaska is nearly two times higher than the population of Alaska as a whole (71 v. 47 per 100,000; Alaska DHSS Bull. 1/29/21), a pattern observed in AI/AN population nationwide (CDC MMWR 12/11/20). Even with these challenges, Alaska has one of the lowest COVID-19 hospitalization and fatality rates overall, and one of the highest rates of COVID-19 vaccination. Sequencing of SARS-CoV-2 genomes has emerged as the key technology for analyzing spread of SARS-CoV-2 lineages, including detection of VOC that may cause more rapid spread, more severe disease, or reduce vaccine efficacy. Importantly, through early capacity-building by the Alaska DHSS Public Health Lab (PHL), in partnership with the University of Alaska and Alaska INBRE, over 500 SARS-CoV-2 genomes have been sequenced and released (GISAID), including recent cases of B.1.1.7, B.1.429, and P.1 variants of concern (VOC). Thus, it is important to understand the geographical and temporal spread of SARS-CoV-2 lineages in the state, and specifically in the AI/AN population. In response to this NIGMS NOSI, the Alaska INBRE (IDeA) program is proposing to extend the genomic surveillance for SARS-CoV-2 lineages and variants in Alaska, with a team of University of Alaska researchers (at UA-Fairbanks and UA-Anchorage), in collaboration with the Southcentral Foundation (SCF) and Alaska Native Medical Center (ANMC) AI/AN health networks, and support from other partners including the Alaska DHSS PHL and CDC Arctic Investigations. The project goals are (1) Prospective genomic sequencing of VOC and VOI in Alaska and comparison to other regions; (2) Prospective genomic sequencing of VOC/VOI in AI/AN health networks to understand COVID-19 disparities; and (3) Geographic and temporal analysis of SARS-CoV-2 in Alaska to inform epidemiological understanding. We will leverage both short-read (Illumina) and long-read (Nanopore) sequencing platforms, and bioinformatics expertise built by Alaska INBRE, to analyze SARS-CoV-2 genomes with samples provided by Alaska DHSS/PHL, and specifically in AI/AN (SCF and ANMC served) populations. Data will be released for meta-analyses to provide genomics perspective to epidemic tracing, understanding of spread of novel lineages, and impact of health disparities.", "keywords": [ "2019-nCoV", "Address", "Adult", "Alaska", "Alaska Native", "American Indians", "Archives", "Arctic Regions", "Awareness", "Back", "Bioinformatics", "Biomedical Research", "Blood Circulation", "COVID-19", "COVID-19 disparity", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 surveillance", "COVID-19 testing", "COVID-19 vaccination", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Collaborations", "Communication", "Data", "Detection", "Diagnostic", "Disease", "Disease Outbreaks", "Epidemic", "Epidemiology", "Evaluation", "Event", "Fatality rate", "Foundations", "Funding", "Genbank", "Genetic", "Genome", "Genomics", "Geographic Distribution", "Geographic Locations", "Geography", "Goals", "Health", "Health Personnel", "Health Services", "Hospitalization", "Investigation", "Knowledge", "Lead", "Medical center", "Meta-Analysis", "Molecular", "National Institute of General Medical Sciences", "Native-Born", "Pattern", "Performance", "Population", "Primary Health Care", "Public Domains", "Public Health", "Reporting", "Research Infrastructure", "Research Personnel", "SARS-CoV-2 B.1.1.7", "SARS-CoV-2 genome", "SARS-CoV-2 positive", "SARS-CoV-2 variant", "Sampling", "Social Work", "Specimen", "Surveillance Program", "Technology", "Time", "United Kingdom", "United States", "United States Public Health Service", "Universities", "Variant", "biological specimen archives", "coronavirus disease", "fighting", "genome sequencing", "health disparity", "health organization", "health professional shortage areas", "hospitalization rates", "innovation", "insight", "interest", "nanopore", "novel", "pandemic disease", "population based", "programs", "prospective", "response", "sample archive", "sequencing platform", "severe COVID-19", "tribal health", "vaccine efficacy", "variant detection", "variants of concern", "virology", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "5500", "attributes": { "award_id": "3R01DK119936-04S1", "title": "New Strategy to Improve Gastrointestinal Health in SIV/HIV", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 19144, "first_name": "KHOA DINH DANG", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-09-04", "end_date": "2023-06-30", "award_amount": 690235, "principal_investigator": { "id": 19145, "first_name": "CRISTIAN", "last_name": "APETREI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "A coronavirus pandemic is currently in progress and a tremendous effort for developing effective vaccines to curb it is currently being made. Adenovirus (Ad)-based vaccines are in the lead in the clinical trials, and it is to be expected that at least one vaccine formulation will comprise of an Ad vector. These vectors are known for inducing massive activation of the immune responses at the mucosal sites. The gastrointestinal (GI) tract is the primary site of HIV replication and CD4+ T cell depletion. HIV induces major alterations at the mucosal sites, which impact their barrier function, permitting transfer of microbial products from the intestinal lumen into the surrounding tissues and general circulation. Microbial translocation is a key driver of the chronic immune activation and inflammation (IA/INFL) that are responsible for HIV disease progression. IA/INFL have a tremendous impact on the outcome of HIV infection and persist even in subjects on antiretroviral therapy (ART), preventing a proper recovery of the CD4+ T cells and thus being responsible for comorbidities and accelerated aging. Improving gut health and controlling chronic IA/INFL is thus one of the major goals both for prevention of HIV-associated comorbidities and for cure strategies. It is conceivable that the use of Ad-based vaccines for the SARS-CoV-2 in people living with HIV may result in high levels of IA/INFL at the mucosal sites, which may reverse HIV control provided by ART. Therefore, we teamedwith Dr. Andrea Gambotto from the University of Pittsburgh, who produced a recombinant type 5 Ad vector encoding the transgene for the antigen SARS-CoV-2 S1 subunit (Ad5.SARS-CoV-2-S1). We will use this vaccine in SIV-infected, ART-suppressed rhesus macaques (RMs) to induce effective mucosal immune responses to SARS-CoV2, and we will monitor the impact of these responses on the key pathogenic features of HIV infection: (a) T-cell immune activation, with particular attention given to the mucosal sites; (b) mucosal inflammation and gut integrity; (c) microbial translocation; (d) microbiome; (e) hypercoagulability; (f) impact on the drug metabolism and viral suppression; (g) impact on the viral reservoirs. Since severe SARS-CoV-2 infection disproportionately target older individuals, both young and old RMs will be included. Our specific aim is to test the impact of a SARS-CoV- 2 vaccine on the gut dysfunction and its consequences, systemic immune activation and inflammation and on the response to ART and viral reservoirs in ART-suppressed SIV infection of young versus old RMs. By directly probing the impact of an Ad5.SARS-CoV-2 S1 vaccine on key parameters of HIV infection, our approach will assess whether the planned COVID-19 vaccination has the potential of being deleterious to HIV- infected subjects. We will also assess the importance of a healthy gastrointestinal mucosa to the efficacy of the SARS-CoV-2 vaccine, which goes beyond the HIV infection field, covering all the inflammatory bowel disease pathology.", "keywords": [ "AIDS prevention", "Acquired Immunodeficiency Syndrome", "Acute", "African", "African Green Monkey", "Aging", "Agreement", "Animals", "Blood Circulation", "CD4 Positive T Lymphocytes", "Characteristics", "Chronic", "Clinical", "Colitis", "Comparative Study", "Data", "Dextran Sulfate", "Disease Progression", "FDA approved", "Food", "Functional disorder", "Future", "Gastrointestinal Hemorrhage", "Gastrointestinal tract structure", "Goals", "Guidelines", "Gut Mucosa", "HIV", "HIV Infections", "Health", "Human", "Immune", "Individual", "Infection", "Inflammation", "Intervention", "Intervention Studies", "Intestinal Motility", "Intestinal Mucosa", "Intestinal Secretions", "Intestines", "Lead", "Lesion", "Macaca", "Maintenance", "Modeling", "Mucous Membrane", "Mus", "Nature", "Octreotide", "Outcome", "Pathogenesis", "Pathogenicity", "Pathology", "Peristalsis", "Pharmaceutical Preparations", "Phenotype", "Plant Roots", "Prevalence", "Recovery", "Relaxation", "Residual state", "Rest", "SIV", "Site", "Somatostatin", "Suggestion", "T-Cell Depletion", "Testing", "Therapeutic", "Therapeutic Intervention", "Tight Junctions", "Tissues", "Vasoactive Intestinal Peptide", "Virus", "Virus Replication", "antiretroviral therapy", "base", "comorbidity", "design", "experimental study", "gastrointestinal", "healing", "immune activation", "improved", "infection management", "irritation", "microbial", "mucosal site", "nonhuman primate", "novel therapeutics", "preservation", "prevent", "repaired", "restoration", "virtual" ], "approved": true } }, { "type": "Grant", "id": "10275", "attributes": { "award_id": "1R34DA057191-01", "title": "Feasibility of pharmacy-delivered patient navigation + virtual buprenorphine + HIV services", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21283, "first_name": "JULIA BETH", "last_name": "Zur", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-15", "end_date": "2025-06-30", "award_amount": 174890, "principal_investigator": { "id": 26231, "first_name": "CRYSTAL FULLER", "last_name": "LEWIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26232, "first_name": "Helen-Maria", "last_name": "Lekas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26233, "first_name": "Babak", "last_name": "Tofighi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Pharmacies are nationally emerging as frontline public health practicing spaces due to their ubiquity, accessibility to medication and screening, and rapid scalability. Independent pharmacies, in particular, have successfully expanded services with greater ease due to the absence of corporate restrictions, including delivery of harm reduction services. Today, linkage to and retention in buprenorphine treatment and HIV prevention and care remains suboptimal in many underserved, HIV burdened communities. The goal of this application is to further expand public health pharmacy practice by exploring on-demand harm reduction services delivered by pharmacy staff in two communities experiencing healthcare system and local community-based services disruptions during COVID-19 (i.e., Harlem and South Bronx in New York City). Building upon two decades of disparities-focused pharmacy-based intervention research via Pharm-Link Studies (2001-2021), and due to recent innovations including telemedicine-based buprenorphine treatment, our team leveraged the NYC Health+Hospitals Virtual Buprenorphine Clinic (VBC) to investigate Pharm-Link/VBC+ which entails in- pharmacy delivery of opioid use disorder (OUD) services (i.e., low-threshold access to telemedicine-based buprenorphine treatment initiation, naloxone dispensation/overdose prevention counseling) linked with HIV services access (i.e., HIV testing/ counseling, PrEP/PEP dispensation, HIV treatment re/initiation) for community/hospital EHR-recruited PWUO. Pharm-Link/VBC+ will also include public health-minded pharmacy staff trained in harm-reduction and social determinants of health-focused patient navigation (SDH-PN) based on use of a SDH checklist and fostered partnerships between pharmacy and community-based services staff. In brief, the specific aims for this developmental R34 proposal are to: (Aim 1) Develop Pharm-Link/VBC+ using in- depth interviews among 3 stakeholder groups (n=10 per group): frontline providers (pharmacists/ technicians/ clerks, buprenorphine prescribers, HIV providers, community-based organization providers), administrators (pharmacy administrators, health department officials), and PWUO with OUD treatment history; (Aim 2) Assess feasibility and usability of implementing Pharm-Link/VBC+ using (a) semi-structured surveys (baseline, 6-, and 12-weeks) among PWUO (n=30) across 3 sequential waves (n=10 per 12-week wave); and (b) administrative data collected from the study pharmacies and Bellevue Hospital EHR; and (Aim 3) Finalize Pharm-Link/VBC+ for R01 scale-up using focus groups (n=3; 6-8/group) among same 3 stakeholder groups, utilizing findings from Aim 2; and conducted and analyzed sequentially such that each group informs the next. These Aims will be accomplished through existing partnerships with two Black-owned independent pharmacies with demonstrated research capacity. Bolstering multi-sectoral approaches to OUD/HIV services infrastructure in low-income Black and Latinx communities experiencing escalating rates of opioid overdose deaths and high HIV burden aligns with federal guidelines to reduce health inequities among PWUO.", "keywords": [ "AIDS prevention", "Administrator", "Area", "Attitude", "Black race", "Buprenorphine", "COVID-19", "Caring", "Clinic", "Clinical", "Communities", "Community Hospitals", "Community Services", "Counseling", "Data", "Development", "Electronic Health Record", "Focus Groups", "Food", "Fostering", "Goals", "Guidelines", "HIV", "Harm Reduction", "Health", "Healthcare Systems", "Hospitals", "Human immunodeficiency virus test", "Infrastructure", "Institutes", "Insurance", "Intervention", "Intervention Studies", "Interview", "Latinx", "Legal", "Link", "Low income", "Mind", "Naloxone", "New York City", "Participant", "Patients", "Persons", "Pharmaceutical Preparations", "Pharmaceutical Services", "Pharmacists", "Pharmacy facility", "Positioning Attribute", "Privacy", "Provider", "Public Assistance", "Public Health", "Public Health Practice", "Recording of previous events", "Research", "Resources", "Retreatment", "SARS-CoV-2 exposure", "Services", "Shelter facility", "Site", "Social Work", "Social support", "Structure", "Support Groups", "Surveys", "Syringes", "System", "Tablet Computer", "Tablets", "Telemedicine", "Telephone", "Testing", "Training", "United States Public Health Service", "Vaccination", "authority", "base", "buprenorphine treatment", "community based service", "community burden", "community partnership", "cost", "design", "disparity reduction", "experience", "flexibility", "health disparity", "health inequalities", "innovation", "medical schools", "opioid mortality", "opioid overdose", "opioid use disorder", "opioid user", "overdose death", "overdose prevention", "pre-exposure prophylaxis", "public health intervention", "recruit", "scale up", "screening", "social health determinants", "social integration", "substance use treatment", "usability", "video visit", "virtual" ], "approved": true } }, { "type": "Grant", "id": "5459", "attributes": { "award_id": "3U01HL146194-03S1", "title": "Innovation Fund Application to the Multicenter AIDS Cohort Study MACS/WIHS Combined Cohort Study (MWCCS) COVID-19 Vaccine Acceptance and Hesitancy (CVHB) Study in People with HIV", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 19021, "first_name": "SEAN FITZGERALD", "last_name": "Altekruse", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-04-01", "end_date": "2026-03-31", "award_amount": 26713, "principal_investigator": { "id": 19023, "first_name": "ADAORA A", "last_name": "ADIMORA", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "MWCCS participants are a high-risk group for severe COVID-19 disease in terms of being HIV-infected, predominately of elderly age, and having numerous underlying comorbidities. Therefore, it is imperative for their health that they be vaccinated with the new COVID-19 vaccines. To date, however, there are only anecdotal data on COVID-19 vaccine acceptance and efficacy in people with HIV (PWH). The MWCCS is ideal for analyzing (a) the acceptancy and effects of COVID-19 vaccine(s) in male and female PWH and matched HIV-uninfected controls (HUC), (b) the impact of age and co-morbidities on vaccine immune response and protection against COVID-19, and (c) the social, economic, and behavioral changes after COVID-19 immunization as compared to the individuals who opted to not take the vaccine.", "keywords": [ "2019-nCoV", "Address", "Age", "Aging", "Attenuated", "Awareness", "Behavioral", "Behavioral Research", "Black race", "COVID-19", "COVID-19 vaccine", "Cardiovascular system", "Characteristics", "Chronic", "Cohort Studies", "Collaborations", "Communication", "Complement", "Data", "Development", "Disease", "Economics", "Elderly", "Eligibility Determination", "Epidemiologic Methods", "Female", "Foundations", "Funding", "Future", "Gender", "HIV", "HIV Infections", "Health", "Immune response", "Immunization", "Immunize", "Incidence", "Individual", "Infection", "Longitudinal observational study", "Lung", "Measures", "Mediating", "Medical", "Medical Records", "Methods", "Monitor", "Neurocognitive", "North Carolina", "Outcome", "Participant", "Pathogenesis", "Patient Self-Report", "Population", "Prevalence", "Research", "Research Personnel", "SARS-CoV-2 infection", "Science", "Serology", "Social status", "Specimen", "Surveys", "The Multicenter AIDS Cohort Study", "Time", "Universities", "Vaccinated", "Vaccination", "Vaccines", "Woman", "Women&apos", "s Interagency HIV Study", "adjudication", "clinical research site", "comorbidity", "disease phenotype", "follow-up", "high risk", "high risk population", "improved", "innovation", "instrument", "male", "male health", "men", "multidisciplinary", "severe COVID-19", "social", "social epidemiology", "vaccine acceptance", "vaccine efficacy", "vaccine hesitancy" ], "approved": true } }, { "type": "Grant", "id": "5510", "attributes": { "award_id": "3R01AA021771-09S1", "title": "ENRICH-2: Stress-Reactivity and Self-Regulation in Infants with Prenatal Alcohol Exposure", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 19171, "first_name": "Benjamin", "last_name": "Xu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2013-07-15", "end_date": "2023-08-31", "award_amount": 69751, "principal_investigator": { "id": 19172, "first_name": "Ludmila Nicole", "last_name": "Bakhireva", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 761, "ror": "", "name": "UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true }, "abstract": "SUMMARY/ABSTRACT The new clinical guidelines for diagnosing Fetal Alcohol Spectrum Disorders (FASD) list self-regulation as one of the key behavioral deficits in children affected by prenatal alcohol exposure (PAE). There is a fundamental gap in knowledge about the underlying mechanisms, spectrum, and severity of such deficits early in life and the best analytical approaches to identify them. In addition, the effect of prenatal stress and postnatal environment on PAE-induced alterations is poorly understood. In this renewal application of the Ethanol, Neurodevelopment, Infant, and Child Health (ENRICH) study, we seek continuous support for our established recruitment/retention pipeline, and propose new highly innovative studies of stress reactivity/regulation in infants with PAE. The long-term goal is to identify indices of atypical brain development following PAE as early as possible to enable early interventions. The objective of this application is to continue our focus on moderate PAE and to evaluate PAE effects on infant stress reactivity/regulation and the mechanisms underpinning altered hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system (ANS) functioning. We will evaluate the relationship between PAE (exposure of interest), prenatal stress (moderator), biological measures of HPA axis (mediators), and physiological and behavioral measures of stress reactivity/regulation in infants (outcomes). The rationale for this proposal is driven by the conviction that HPA and ANS dysregulation leading to altered stress reactivity/regulation in children with PAE might be the basis for some of the key PAE-induced behavioral deficits, and increased vulnerability to secondary disabilities. The central hypothesis is that PAE will be associated with heightened infant stress reactivity and poorer self-regulation (beyond the effect of prenatal stress) through fetal programming of the HPA axis. This hypothesis has been formulated on the basis of preclinical data at UNM and clinical data from the current funding cycle of ENRICH-1 and will be tested by pursuing three specific aims, which evaluate the contributing effects of PAE on 1) Programming of the fetal HPA axis, assessed as expression of key placental and umbilical cord markers of HPA axis; 2) Infant physiological reactivity (heart rate variability [HRV]) dynamic changes during basal-stressor-recovery periods assessed in the newborn period and at 6-months of age; 3) Infant behavioral reactivity and regulation assessed in the newborn period and at 6-months of age. The comprehensive multi-systemic approach employed in this study is highly innovative and has not previously been used. Innovation is further driven by our focus on moderate PAE and ability to assess the trajectory of impaired stress reactivity/regulation (newborn, 6-months evaluations) in a large prospective cohort study. This research is significant because it involves comprehensive repeated-measures assessment of neuroendocrine, electrophysiological, and behavioral indices of impaired stress reactivity/regulation, which will lead to refinement of analytical techniques for accurate identification of PAE deficits in infancy before higher-order behavioral deficits manifest.", "keywords": [ "Address", "Adrenal Glands", "Affect", "Age-Months", "Alcohols", "Area", "Arousal", "Autonomic nervous system", "Behavioral", "Biological", "Biological Markers", "Brain", "Caregivers", "Child", "Child Health", "Classification", "Clinical", "Clinical Data", "Collection", "Corticotropin-Releasing Hormone", "Cortisone", "DSM-V", "Data", "Development", "Diagnostic", "Disease", "Early Intervention", "Electrophysiology (science)", "Environment", "Enzymes", "Ethanol", "Evaluation", "Exposure to", "Face", "Fetal Alcohol Exposure", "Fetal Alcohol Spectrum Disorder", "Fetal alcohol effects", "Funding", "Glucocorticoid Receptor", "Goals", "Grant", "Guidelines", "Health", "Human", "Hydrocortisone", "Hypothalamic structure", "Impairment", "Infant", "Infant Health", "Informal Social Control", "Infrastructure", "Interview", "Knowledge", "Life", "Literature", "Longevity", "Measures", "Mediating", "Mediator of activation protein", "NR3C1 gene", "National Institute on Alcohol Abuse and Alcoholism", "Nervous System Physiology", "Neurodevelopmental Disorder", "Neurosecretory Systems", "New Mexico", "Newborn Infant", "Outcome", "Paper", "Peer Review", "Physiological", "Pituitary Gland", "Procedures", "Prospective cohort", "Prospective cohort study", "Public Health", "Publishing", "Recovery", "Regulation", "Reporting", "Research", "Secondary to", "Services", "Severities", "Specimen", "Stress", "Techniques", "Testing", "Time", "Umbilical Cord Blood", "Umbilical cord structure", "Update", "behavior measurement", "clinical care", "cognitive function", "cohort", "convict", "disability", "fetal", "fetal diagnosis", "fetal programming", "heart rate variability", "hypothalamic-pituitary-adrenal axis", "indexing", "infancy", "infant outcome", "innovation", "interest", "negative affect", "neurodevelopment", "neuroimaging", "novel", "novel strategies", "overexpression", "postnatal", "pre-clinical", "prenatal stress", "prospective", "recruit", "response", "stress reactivity", "stressor" ], "approved": true } }, { "type": "Grant", "id": "10363", "attributes": { "award_id": "1RF1MH132348-01", "title": "Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 7956, "first_name": "Jennifer", "last_name": "Villatte", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 2368492, "principal_investigator": { "id": 26335, "first_name": "Philip Andrew", "last_name": "Chan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26336, "first_name": "Ethan", "last_name": "Moitra", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 222, "ror": "https://ror.org/05gq02987", "name": "Brown University", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "During the COVID-19 pandemic, up to 81% of adults in the United States experienced worsening mental health. A major cause was the social isolation triggered by the pandemic due to quarantining, loss of family or friends, and loss of work. For individuals who lost social connections or were unable to adapt to maintain their connections, social support decreased and loneliness worsened, putting them at much higher risk for anxiety and depressive symptoms. Importantly, people who identify as LGBTQ+ have been particularly affected by the social isolation caused by the pandemic and were already at much higher risk of social isolation, loneliness, and mental illness, including suicidality, before the pandemic. The long-term goal is to improve mental health outcomes in the LGBTQ+ population. The objective of this R01 fully-powered Hybrid Type 1 Effectiveness- Implementation trial is to examine the effectiveness of a brief acceptance-based behavioral telehealth intervention (ABBT) to improve mental health during the COVID-19 pandemic by strengthening social support among LGBTQ+ individuals. The central hypothesis is that ABBT will be an impactful intervention for LGBTQ+ individuals because it will teach patients how to navigate the real, unavoidable challenges of the COVID-19 pandemic, while attending to their life goals and values, such as social connectedness. The aims of this proposal are: (1) to examine the effectiveness of ABBT in reducing mental health morbidity by conducting a fully-powered, RCT (n=200) of ABBT vs. Treatment-as-Usual; (2) to examine potential mediators and moderators of ABBT treatment effects; and, (3) to identify patient, staff, and organizational-level factors that may facilitate/hinder ABBT implementation. Primary outcomes will be anxiety and depressive symptoms. ABBT represents an innovative approach to coping with the COVID-19 pandemic that can be more personally-relevant and sensitive to patients' needs than traditional CBT. Thus, the clinical and public health significance of this research will be the demonstration of a simple, lower-cost, and potentially widely- disseminable intervention that can be integrated into treatment services at LGBTQ+ health centers.", "keywords": [ "Address", "Administrator", "Adoption", "Adult", "Affect", "Anxiety Disorders", "Award", "Behavior Therapy", "Behavioral", "Blinded", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Clinical", "Cognitive Therapy", "Collaborations", "Communities", "Data", "Diagnosis", "Disputes", "Effectiveness", "Effectiveness of Interventions", "Electronic Health Record", "Family", "Friends", "Goals", "Health", "Healthcare", "Hybrids", "Individual", "Intervention", "Interview", "Investigational Therapies", "Lesbian Gay Bisexual Transgender Queer", "Life", "Loneliness", "Mediating", "Mediator of activation protein", "Mental Health", "Mental disorders", "Mood Disorders", "Morbidity - disease rate", "Motivation", "National Institute of Mental Health", "Neighborhood Health Center", "Outcome", "Participant", "Pathway interactions", "Patient Self-Report", "Patients", "Perception", "Personal Satisfaction", "Persons", "Physicians", "Population", "Promoting Action on Research Implementation in Health Services framework", "Psychiatric Diagnosis", "Psychologist", "Public Health", "Quarantine", "Reach Effectiveness Adoption Implementation and Maintenance", "Recording of previous events", "Recovery", "Research", "Resources", "Rhode Island", "Social isolation", "Social support", "Societies", "Speed", "Strategic Planning", "Suicide", "Symptoms", "Testing", "Translations", "United States", "Work", "anxiety symptoms", "base", "clinical care", "clinical practice", "coping", "cost", "depressive symptoms", "distraction", "effectiveness implementation trial", "effectiveness testing", "experience", "follow-up", "future implementation", "health disparity", "health equity", "high risk", "hybrid type 1 design", "implementation barriers", "implementation fidelity", "implementation framework", "implementation intervention", "improved", "innovation", "mindfulness", "pandemic disease", "primary outcome", "recruit", "response", "secondary outcome", "social", "telehealth", "tool", "treatment as usual", "treatment effect", "treatment services", "uptake" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1392, "count": 13920 } } }